Farnesyl:protein transferase (FPTase) catalyzes the covalent addition of the isoprenyl moiety of farnesylpyrophosphate to the C-terminus of the Ras oncoprotein and other cellular proteins. Inhibitors of FPTase (FTIs) have been developed as potential anticancer agents, and several compounds have been evaluated in clinical trials. To facilitate the identification of cell-active FTIs with high potency, the authors developed a method that uses a radiolabeled FTI that serves as a ligand in competitive displacement assays. Using high-affinity [ 3 H]-labeled or [ 125 I]-labeled FTI radioligands, they show that specific binding to FPTase can be detected in intact cells. Binding of these labeled FTI radioligands can be competed with a variety of structurally diverse FTIs, and the authors show that inhibition of FTI radioligand binding correlates well with inhibition of FPTase substrate prenylation in cells. This method provides a rapid and quantitative means of assessing FTI potency in cells and is useful for guiding the discovery of potent, novel inhibitors of FPTase. Similar methods could be employed in the optimization of inhibitors for other intracellular drug targets. (Journal of Biomolecular Screening 2003:430-438) 
INTRODUCTION
A variety of cellular proteins are modified at their C-terminus with an isoprenoid lipid consisting of either the 15-carbon farnesyl isoprenoid or the 20-carbon geranylgeranyl isoprenoid (reviewed in Zhang and Casey 1 ). These lipid modifications function to anchor the protein at cellular membranes and are performed by the so-called CAAX protein:prenyl transferases, either farnesyl:protein transferase (FPTase) in the case of farnesylation or geranylgeranyl:protein transferase type I (GGPTase-I) in the case of geranylgeranylation. The CAAX prenyltransferases, which add the isoprenoid lipid to cysteine residue 4 amino acids from the Cterminus of the protein substrate, are related heterodimeric enzymes that share a common α subunit. The sequence of the CA 1 A 2 X motif, where C is cysteine, A is typically an aliphatic amino acid, and X is any amino acid, determines whether a protein is modified by FPTase or GGPTase-I. In general, proteins in which X is serine or methionine are farnesylated, whereas proteins in which X is leucine are geranylgeranylated. A third type of prenyl:protein transferase, geranylgeranyl:protein transferase type II (GGPTase-II), is involved exclusively in modification of the Rab family of proteins, which are geranylgeranylated on 2 cysteine residues found in CC, CXC, or CCXX motifs at the C-termini of these proteins.
Included in the class of prenylated proteins are the Ras proteins, 21-kDa guanosine triphosphate (GTP) binding proteins that play a central role in the control of cell growth. Oncogenic forms of Ras, which are transforming to cells due to mutations that inactivate their GTPase activity and thereby keep the Ras protein in a permanently activated state, are highly prevalent in human cancers. The 4 isoforms of Ras-2 splicing variants of the Ki-ras gene (Ki4A-Ras and Ki4B-Ras) and the Ha-Ras and N-Ras isoforms-are normally farnesylated. Because wild-type and oncogenic Ras require prenylation for their biological and/or transforming functions, [2] [3] [4] [5] FPTase has been viewed as an attractive, pharmaceutically tractable cancer target. 6 Over the past decade, a variety of FPTase inhibitors have been developed, some of which have been advanced into clinical trials. 7, 8 Although inhibitors of FPTase (FTIs) suitable for clinical evaluation have been developed, there may be a need to identify second-generation compounds with superior potency, selectivity, and other improved pharmaceutical characteristics. As is the case with any intracellular drug target, development of cell-active FTIs requires that the compound not only possess sufficient intrinsic po-tency but also have suitable physiochemical properties that allow for cell membrane penetration. In addition, compounds should lack activity toward drug efflux transporters such as Pglycoprotein, which can be upregulated in drug-resistant cancers. Determination of FTI potency in cells has typically relied on immunoblotting methods in which the inhibition of prenylation of FPTase protein substrates can be followed by the difference in mobility in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) between prenylated and unprenylated forms of the protein substrate (see, e.g., Lobell et al. 9 ). Although the immunoblot methods are reliable indicators of FPTase activity, they are laborious and low throughput. FTI potency in cells can also be assessed by cell proliferation assays that, although being reasonably quantitative, are time-consuming and only provide an indirect measure of FTI activity. We therefore developed a more rapid and precise method for assessing FTI potency in cells that employs a radiolabeled FTI to serve as a ligand in a competitive displacement assay. This method has been recently employed in the development of the structure-activity relationship of several distinct classes of FTIs. [10] [11] [12] (methylsulfonyl)ethyl]-5-oxopiperazin-1-yl}methyl)-1Himidazol-1-yl]methyl}benzonitrile) has been described. 13 The radioiodinated product was purified via HPLC and specific activity determined by comparing the relative saturation compared to [ 3 H]FTI-1 as a standard.
MATERIALS AND METHODS

Radiochemical synthesis
[ 3 H]FTI-1 (4-{[5-({(2S)-4-(3-[H-3]phenyl)-2-[2-butyl]-5- oxopiperazin-1-yl}methyl)-1H-imidazol-1-yl]methyl}
Cell culture FTI radioligand binding assays
Rat1 cells transformed with v-Ha-ras 14 were used for most of the radiotracer binding studies, unless indicated otherwise. KB-3-1 and KB-V-1 cells were obtained from Dr. Michael Gottesman (National Institute of Health, Bethesda, MD). Other human tumor cell lines were obtained from the ATCC (Manassas, VA). In the binding studies, the size of the tissue culture plate and the number of cells per plate varied between experiments, with a typical experiment using 5 million Rat1 cells per 10-cm plate (58 cm 2 surface area). Cells were cultured with growth medium containing fetal bovine serum (FBS) (10% in the case of Rat1 cells), and radiotracer was added. Initial binding studies were conducted using [ 3 H]FTI-1 at a concentration of 0.2 nM for either the equilibration time studies or equilibrium competition assays. For saturation binding, we used [ 3 H]FTI-1 at concentrations from 0.1 to 2 nM in-cubated for 120 min in the presence and absence of saturating FTI-3 ( Fig. 1 ) to demonstrate specific binding. Initial time course studies for [ 125 I]FTI-2 were also conducted using the 10-cm plates. Because the specific activities of the radioiodinated radiotracer are considerably higher, we turned to a 24-well format (2 cm 2 surface area), which provided a good count rate of bound [ 125 I]FTI-2.
Data from either [ 3 H]FTI-1 or [ 125 I]FTI-2 were converted to dpm/well or plate, then expressed as fmoles bound/well. For saturation studies, the data were plotted versus radioligand concentrations, and then the data were curve fitted using a single-site binding model in SigmaPlot. To determine the specific activity of the radioiodinated radioligand, we expressed the maximum binding determined from the saturation studies using [ a concentration of 1 nM, along with the desired concentration of test FTI, and then added to the cell monolayers. After a 4-h incubation at 37°C, the cells were briefly rinsed with phosphate-buffered saline, removed from the culture plate by trypsinization, and then subjected to gamma counting using a Cobra II gamma counter (PerkinElmer Life Sciences, Downers Grove, IL). Data from the dose inhibition curves were first curve fit as counts/well versus the concentrations of the unlabeled FTIs using a single-site, 4-parameter model in SigmaPlot. Using the parameters thus obtained for uninhibited count rates and maximum inhibition (nonspecific binding), we converted the data to percent specifically bound radiotracer and plotted for presentation. IC 50 values are uncorrected for the concentration of radiotracer present because intracellular concentrations may be different from that present in the added medium.
RESULTS
High-affinity binding of FTI radiotracers in cells
Two radiolabeled, CAAX-competitive FTIs based on a core Narylpiperazinone structure 15 (Fig. 1 ) were evaluated. When added to ras-transformed Rat1 fibroblasts in culture, [ 3 H]FTI-1 accumulated in a time-dependent manner, achieving a maximal signal and reaching an apparent equilibrium by~1 h ( Fig. 2A) . This timedependent cellular accumulation of [ 3 H]FTI-1 reflected binding to high-affinity FPTase sites because coincubation with a 1000-fold molar excess of a structurally different compound (FTI-3, Fig. 1 ) inhibited binding of the tracer to cells ( Fig Table 1) .
The other FTI radiotracer described here, [ 125 I]FTI-2, also displays saturable, high-affinity binding, with an apparent K d of~2 nM (Fig. 3B) . Unexpectedly, the affinity of [ 125 I]FTI-2 is~10-fold lower than that of [ 3 H]FTI-1, even though the intrinsic potency of FTI-2, as measured against purified FPTase in vitro, is approximately 3-fold greater than that of FTI-1 (IC 50 values of 0.3 nM and 0.13 nM for FTI-1 and FTI-2, respectively, were determined as described in Graham et al. 16 [data not shown]). By contrast, the dissociation rate constant of [ 125 I]FTI-2, (k -1 ) of 0.009 min -1 , is somewhat lower than that of [ 3 H]FTI-1 ( Fig. 3C ) and therefore is reflective of its intrinsic potency. Furthermore, [ 125 I]FTI-2 showed a slower rate of uptake in Rat1 cells compared to [ 3 H]FTI-1, taking 3 h to reach maximal binding (Fig. 3A) , approximately 2 h longer than the time required for [ 3 H]FTI-1 to reach maximal binding ( Fig. 2A ). Table 1 ).
Effect of P-glycoprotein on FTI radiotracer binding
We considered the possibility that drug efflux mechanisms, including pumping by the P-glycoprotein (Pgp) encoded by the MDR1 multidrug transporter gene, could affect the rate of radiotracer uptake into the cell and the apparent affinity of the radiotracer. To explore this possibility, we employed a matched pair of cell lines, KB-3-1 and KB-V-1. The KB-V-1 line, which was derived from KB-3-1 through a selection process involving exposure to increasing concentrations of vinblastine, 17 expresses high levels of Pgp. As seen in Figure 4A , the uptake and binding of [ 3 H]FTI-1 in KB-V-1 cells is negligible compared to its binding in KB-3-1. Furthermore, addition of the Pgp inhibitor verapamil 18 resulted in comparable binding of [ 3 H]FTI-1 to both KB-3-1 and KB-V-1. Interestingly, verapamil also enhanced the binding of [ 3 H]FTI-1 in the KB-3-1 cells, suggesting a low basal level of Pgp activity or a different pump that is also inhibited by verapamil ( Fig.  4B ). [ 125 I]FTI-2 also shows specific binding in KB-3-1 but not in KB-V-1 (data not shown). In addition, we found that the binding of [ 125 I]FTI-2 to Ha-ras-transformed Rat1 cells was increased by approximately 2.5-fold in a dose-dependent manner by a variety of agents-including verapamil, cyclosporin A, amiodarone, quinacrine, and quinidine-that are known modulators of Pgp (data not shown). 18 Furthermore, addition of verapamil to Ha-rastransformed Rat1 cells decreased the apparent K d of [ 125 I]FTI-2 by approximately 2-fold (Table 1 ). These studies indicate that both [ 3 H]FTI-1 and [ 125 I]FTI-2 are subject to Pgp-mediated drug export. The apparent K d of the radiotracer may thus be influenced in part by this drug efflux mechanism, although we note that inhibition of the MDR1 Pgp transporter may not fully account for the discrepancy between intrinsic potency and apparent affinity in cells between [ 3 H]FTI-1 and [ 125 I]FTI-2. Further analysis will be required to determine if other drug efflux mechanisms, such as transport via the multi-drug resistance protein family of transporters, 19 can also Table 1 ).
influence FTI radiotracer binding and might thus account for the relative differences between in vitro potency and apparent K d in cells between [ 3 H]FTI-1 and [ 125 I]FTI-2.
Determination of FTI cell potency via a competition binding assay with FTI radiotracers
We assessed whether the FTI radioligands shown in Figure 1 could be used in competitive binding assays for the determination of the relative potencies of unlabeled FTIs. We refer to these assays by the acronym CRAFTI, for cellular radiotracer assay of farnesyltransferase inhibitors. In CRAFTI, cell monolayers were incubated with FTI radioligand at a concentration equal to the ap-parent K d for radiotracer in the presence of increasing concentrations of unlabeled competitor compound. As seen in Figure 5 , unlabeled FTIs inhibited the binding of radioligand to cells in a dose-dependent manner. The rank order of inhibition of radioligand binding by the unlabeled FTIs was comparable between the 2 radioligands, suggesting that the radiotracers bind to a common binding site in cells.
We sought more evidence that the radiotracer was binding to FPTase in cells and that the IC 50 determined in CRAFTI reflected the potency of the compound for binding to FPTase. To do this, we compared the IC 50 of 22 structurally divergent FTIs in CRAFTI to the IC 50 determined in an immunoblot assay that measures the inhibition of farnesylation of a molecular chaperone protein, HDJ2, which is a substrate for FPTase. 20, 21 For this comparison, a human pancreatic tumor cell line, PSN-1, was used. In the HDJ2 farnesylation assay, prenylated (farnesylated) and nonprenylated forms of HDJ2 are distinguished based on their different electrophoretic mobility, and the IC 50 is determined by quantifying the relative amount of unprenylated HDJ2 produced by varying doses of the FTI. 9 As seen in Figure 6A , a correlation (r 2 = 0.9) was observed between the IC 50 determined in these 2 assays, confirming that the radioligand competition binding assay provides an accurate measure of a compound's ability to bind to and inhibit FPTase in cells. Typically, we have observed that compounds appear approximately 10-fold more potent when assayed by CRAFTI as compared to their potency assayed by inhibition of HDJ2 farnesylation. This difference suggests that significantly greater occupancy of the enzyme by the inhibitor is required to inhibit farnesylation of HDJ2, as compared to the occupancy required to compete with the radiotracer.
Because FTIs inhibit the growth of cells in culture, we examined the ability of the CRAFTI assay to predict potency of FTIs as inhibitors of cell growth. For this purpose, we employed an anchorage-independent growth assay using Ha-ras-transformed Rat1 cells. As expected (Fig. 6B ), a correlation (r 2 = 0.843) was seen between CRAFTI and the anchorage-independent growth assay.
Although correlations were established between CRAFTI and other cellular assays measuring FPTase inhibition, we observe a low degree of correlation (r 2 = 0.5) between the intrinsic FPTase inhibitory activity of compounds measured against purified enzyme in vitro and the potency of these compounds in cells measured by CRAFTI (Fig. 6C) . In some cases, compounds with equivalent intrinsic potency for inhibition of FPTase displayed a range of poten- Screening 8(4); 2003 www.sbsonline.org 435 FIG. 6. Correlation between cellular radiotracer assay of farnesyltransferase inhibitors (CRAFTI) and other assays for farnesyl:protein transferase (FPTase) inhibition in cells and in vitro. (A) Correlation between CRAFTI and HDJ2 farnesylation assay. IC 50 s for inhibition of HDJ2 farnesylation were determined as previously described. 9 Both assays were run in PSN-1 tumor cells; 22 FTIs were compared. Linear correlation provides r 2 = 0.90. (B) Correlation between CRAFTI and an anchorage-independent growth assay. IC 50 s for the inhibition of anchorage-independent growth were determined essentially as described in Fukazawa et al., 22 except that cells were cultured for 6 days prior to termination of the experiment. Both assays were run using Ha-rastransformed Rat1 cells; 262 FTIs were compared. Linear correlation provides r 2 = 0.84. (C) Correlation between CRAFTI and the in vitro inhibition of purified FPTase. A total of 1650 FTIs were assessed in both assays. Linear correlation provided r 2 = 0.50. IC 50 s against purified FPTase were determined as described in Graham et al. 16 The compounds compared in these assays represented a diverse group of FTI structures, many of which have been described elsewhere (see, e.g., Beshore et al., 11 MacTough et al., 12 Bell et al., 23 Dinsmore et al., 24 and Nguyen et al.
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cies against the enzyme in cells that spanned a range of 3 or more orders of magnitude. A compound capable of inhibiting an intracellular target must not only have sufficient intrinsic potency for the target but must also have suitable physiochemical properties that enable cell membrane penetration, intracellular retention, and compound stability. Drug efflux due to the Pgp transporters could be 1 factor that contributes to the lack of correlation between intrinsic potency and activity in cells. To investigate this possibility, we focused on L-778,123 (FTI-5), a compound evaluated in clinical trials by Merck & Co., 26 and a related compound, FTI-6. FTI-6 is a 10-fold more potent inhibitor of FPTase than FTI-5 in vitro (IC 50 0.2 nM and 2.0 nM for FTI-6 and FTI-5, respectively, as determined as described in Graham et al. 16 [data not shown]). As seen in Figure 7A , the 2 compounds are equipotent inhibitors in H-ras-transformed Rat1 cells, as measured by CRAFTI (Mean IC 50 3.5 [n = 16] and 3.6 [n = 105] for FTI-6 and FTI-5, respectively). However, when the Pgp antagonist verapamil was added to the radioligand binding assay, FTI-6 was 10-fold more potent in CRAFTI than FTI-5, reflecting the 10-fold greater intrinsic potency of FTI-6 ( Fig. 7A) . These data suggest that although FTI-6 is intrinsically a more potent inhibitor of FPTase than FTI-5, its cellular potency may be reduced relative to FTI-5 because it is a better substrate for Pgp. To confirm this, we assessed the ability of FTI-6 and FTI-5 to inhibit farnesylation of HDJ2 in KB-3-1 and KB-V-1 cells. In KB-3-1 cells, FTI-6 was approximately 30-fold more potent than FTI-5 in inhibiting HDJ2 farnesylation, whereas in the KB-V-1 line that overexpresses Pgp, FTI-6 was about 3-fold less potent than FTI-5 (Fig. 7B) . These results confirm that FTI-6 is more sensitive to Pgp expression than FTI-5 and suggest that drug efflux via Pgp is one likely mechanism that contributes to the low correlation coefficient between in vitro FPTase inhibition and cellular potency measured by CRAFTI ( Fig.  6C ). Other mechanisms such as poor membrane permeability of some compounds likely contribute to the low correlation between the in vitro and the cellular assays.
DISCUSSION
We have developed an assay (CRAFTI) that uses an FTI radiotracer as a probe for assessing the potency of FTIs in living cells. This assay played a critical role in the selection of FTI-5 as a clinical candidate tested as an anticancer agent in man 26 and was recently used in identifying some of the most highly potent FTIs described to date. 23 CRAFTI is able to discriminate between a variety of structurally diverse compounds that differ in potency over at least 7 orders of magnitude ( Fig. 6 ).
For most of our studies, we chose to use [ 125 I]FTI-2 as the radiotracer instead of [ 3 H]FTI-1. This choice was based on 2 advantages of working with the isotope, I-125. First, [ 125 I] does not require sample solubilization or use of scintillation cocktails for counting. Second, adequate signal to noise can be obtained with smaller numbers of cells with the [ 125 I]-labeled tracer compared to the [ 3 H] tracer, and thus the [ 125 I] tracer could be used in a multiwell assay format. The radioligand competition binding assay we developed proved to be a rapid, quantitative, moderate throughput cell-based assay that facilitated the establishment of structureactivity relationships in our FTI discovery program. Using 24-well assay plates and manual multichannel pipetting devices, we routinely determined the IC 50 , derived from a 6-point titration, for 40 compounds in an experiment requiring approximately 6 hours to complete. For comparison, approximately 2 days of hands-on time are required to determine the IC 50 for 8 compounds in the HDJ2 farnesylation (immunoblotting) assay. Although CRAFTI can be performed in virtually any cell line, we have found that the IC 50 of a compound can vary significantly from one cell line to another. This variation could be due to drug efflux mechanisms, and we have demonstrated that MDR expression in a cell line can greatly influence the observed IC 50 (Fig. 7) . The radiotracers described here are subject to drug efflux via the Pglycoprotein pump, as demonstrated by an increase in tracer uptake by MDR inhibitors such as verapamil (Fig. 4 ). CRAFTI can be performed in the presence of verapamil, and the fold-shift in IC 50 observed upon verapamil addition can provide a measure of a compound's ability to be pumped by P-glycoprotein (Fig. 7) . This provides a convenient means of assessing a compound's potency for FPTase in a cell as well as the undesired activity toward Pglycoprotein.
Although radiotracers have been widely used as research tools for imaging studies involving receptor antagonists, they have seen limited use as probes for studying intracellular targets. In this study, we have described the utility of FTI radiotracers in cell culture models. We have also used related FTI radiotracers in competitive binding assays and imaging studies in animal models to study the tissue distribution of FTIs and to characterize FPTase occupancy in tumor and normal tissues. These in vivo studies will be described elsewhere (R. Gibson et al., manuscript in preparation). Finally, although we have discussed radiotracers specifically for FPTase in cell culture, this assay represents a general paradigm that may be useful for any enzyme with sufficient concentration in cells to provide a specific binding signal with a radiotracer.
